Danish allergy vaccine company ALK has announced in a press release that its tablet vaccine for grass pollen allergy, Grazax, has been approved by authorities in 27 European countries as a disease-modifying allergy treatment. This makes Grazax the only registered tablet treatment for grass pollen allergy with a documented sustained effect after completion of treatment.
The approval and extended marketing authorisation are based on the results of the first follow-up year of a long-term study with Grazax. The results document that the significant improvement of patients' eye and nose symptoms and quality of life is sustained after completion of the recommended treatment regimen.
"Patients cannot obtain such a sustained disease modifying effect with traditional symptom-relieving allergy medications such as antihistamines and/or nasal corticosteroids," ALK writes in the press release.
Per Plotnikov, head of investor relations in ALK told national daily newspaper Jyllands-Posten that the approval is the preliminary culmination of work that started 10 years ago, and that it will boost sales.
Grazax is currently on sale to adults in 13 European countries. It has also been approved for children in five countries.
Headquartered in Hørsholm north of Copenhagen, ALK has been active in allergy immunotherapy since 1923. The company's product pipeline comprises five tablet-based vaccines in clinical development, four of which are based on standardised natural allergens as the active ingredient, while the fifth is based on recombinant allergens. ALK employs approximately 1,500 people and has subsidiaries, production facilities and distributors throughout the world. The company is listed on the NASDAQ OMX Copenhagen.